120 related articles for article (PubMed ID: 31646390)
21. Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF.
Tinholt M; Vollan HK; Sahlberg KK; Jernström S; Kaveh F; Lingjærde OC; Kåresen R; Sauer T; Kristensen V; Børresen-Dale AL; Sandset PM; Iversen N
Breast Cancer Res; 2015 Mar; 17(1):44. PubMed ID: 25882602
[TBL] [Abstract][Full Text] [Related]
22. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D
J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712
[TBL] [Abstract][Full Text] [Related]
23. MARCKS protein overexpression in inflammatory breast cancer.
Manai M; Thomassin-Piana J; Gamoudi A; Finetti P; Lopez M; Eghozzi R; Ayadi S; Lamine OB; Manai M; Rahal K; Charafe-Jauffret E; Jacquemier J; Viens P; Birnbaum D; Boussen H; Chaffanet M; Bertucci F
Oncotarget; 2017 Jan; 8(4):6246-6257. PubMed ID: 28009981
[TBL] [Abstract][Full Text] [Related]
24. Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers.
Sieuwerts AM; Willis S; Burns MB; Look MP; Meijer-Van Gelder ME; Schlicker A; Heideman MR; Jacobs H; Wessels L; Leyland-Jones B; Gray KP; Foekens JA; Harris RS; Martens JW
Horm Cancer; 2014 Dec; 5(6):405-13. PubMed ID: 25123150
[TBL] [Abstract][Full Text] [Related]
25. The role of circulating tumor cells and K-ras mutations in patients with locally advanced rectal cancer: a prospective study.
Bahnassy AA; Abdel-Azim YA; Ezzat S; Abdellateif MS; Zekri AN; Mohanad M; Salama A; Khaled H
Mol Biol Rep; 2020 Dec; 47(12):9645-9657. PubMed ID: 33174084
[TBL] [Abstract][Full Text] [Related]
26. Correlation between RAS Test Results and Prognosis of Metastatic Colorectal Cancer Patients: a Report from Western Iran.
Payandeh M; Shazad B; Sadeghi M; Shahbazi M
Asian Pac J Cancer Prev; 2016; 17(4):1729-32. PubMed ID: 27221845
[TBL] [Abstract][Full Text] [Related]
27. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer.
Luhtala S; Staff S; Kallioniemi A; Tanner M; Isola J
BMC Cancer; 2018 Oct; 18(1):1045. PubMed ID: 30367623
[TBL] [Abstract][Full Text] [Related]
29. Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival.
Yardley DA; Kaufman PA; Huang W; Krekow L; Savin M; Lawler WE; Zrada S; Starr A; Einhorn H; Schwartzberg LS; Adams JW; Lie Y; Paquet AC; Sperinde J; Haddad M; Anderson S; Brigino M; Pesano R; Bates MP; Weidler J; Bosserman L
Breast Cancer Res; 2015 Mar; 17(1):41. PubMed ID: 25886996
[TBL] [Abstract][Full Text] [Related]
30. Lnc RNA H19 is associated with poor prognosis in breast cancer patients and promotes cancer stemness.
Shima H; Kida K; Adachi S; Yamada A; Sugae S; Narui K; Miyagi Y; Nishi M; Ryo A; Murata S; Taniguchi H; Ichikawa Y; Ishikawa T; Endo I
Breast Cancer Res Treat; 2018 Aug; 170(3):507-516. PubMed ID: 29693231
[TBL] [Abstract][Full Text] [Related]
31. The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients.
Zhu YY; Si W; Ji TF; Guo XQ; Hu Y; Yang JL
Tumour Biol; 2016 Jun; 37(6):7675-84. PubMed ID: 26687919
[TBL] [Abstract][Full Text] [Related]
32. Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.
Rennstam K; McMichael N; Berglund P; Honeth G; Hegardt C; Rydén L; Luts L; Bendahl PO; Hedenfalk I
Breast Cancer Res Treat; 2010 Jul; 122(2):315-24. PubMed ID: 19795205
[TBL] [Abstract][Full Text] [Related]
33. Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study.
Guren TK; Thomsen M; Kure EH; Sorbye H; Glimelius B; Pfeiffer P; Österlund P; Sigurdsson F; Lothe IMB; Dalsgaard AM; Skovlund E; Christoffersen T; Tveit KM
Br J Cancer; 2017 May; 116(10):1271-1278. PubMed ID: 28399112
[TBL] [Abstract][Full Text] [Related]
34. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
[TBL] [Abstract][Full Text] [Related]
35. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G
J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711
[TBL] [Abstract][Full Text] [Related]
36. Tumor characteristics and prognosis in familial breast cancer.
Arpino G; Pensabene M; Condello C; Ruocco R; Cerillo I; Lauria R; Forestieri V; Giuliano M; De Angelis C; Montella M; Crispo A; De Placido S
BMC Cancer; 2016 Nov; 16(1):924. PubMed ID: 27899083
[TBL] [Abstract][Full Text] [Related]
37. Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors.
Parise CA; Caggiano V
Breast Cancer Res Treat; 2017 Oct; 165(3):743-750. PubMed ID: 28689363
[TBL] [Abstract][Full Text] [Related]
38. RECK is not an independent prognostic marker for breast cancer.
Gomes LR; Fujita A; Mott JD; Soares FA; Labriola L; Sogayar MC
BMC Cancer; 2015 Oct; 15():660. PubMed ID: 26449734
[TBL] [Abstract][Full Text] [Related]
39. Predictive factors on outcomes in metaplastic breast cancer.
Leyrer CM; Berriochoa CA; Agrawal S; Donaldson A; Calhoun BC; Shah C; Stewart R; Moore HCF; Tendulkar RD
Breast Cancer Res Treat; 2017 Oct; 165(3):499-504. PubMed ID: 28689362
[TBL] [Abstract][Full Text] [Related]
40. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A
Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
